Home » The European Medicines Agency Approves Aripiprazole for the Treatment of Moderate to Severe Manic Episodes in Bipolar I Disorder in Adolescents
The European Medicines Agency Approves Aripiprazole for the Treatment of Moderate to Severe Manic Episodes in Bipolar I Disorder in Adolescents
Otsuka Pharmaceutical announced that the European Medicines Agency has approved a label extension for aripiprazole for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 and older.
Otsuka Pharmaceutical
Otsuka Pharmaceutical
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May